Scotland's SMC has approved semaglutide (Wegovy) for free NHS use in overweight patients with established cardiovascular disease, making an estimated 145,000 people eligible under a BMI ≥27 criterion. Trials show early reductions in major cardiac and circulatory events—suggesting benefits beyond weight loss—and the drug is self-administered by pen. Common side effects include nausea and bloating. Clinicians have welcomed the decision as an important step to reduce cardiovascular risk.
Wegovy (Semaglutide) Approved For Free NHS Use In Scotland To Cut Heart Attack And Stroke Risk
Patients can self-administer the drug at home using a special pen injector device [Getty Images]
The Scottish Medicines Consortium (SMC) has approved semaglutide (brand name Wegovy) for NHS use in Scotland as an adjunct to diet and exercise for people who are overweight and have established cardiovascular disease. The move means eligible patients will be able to receive the injection free on the NHS.
Who Is Eligible
Under the SMC guidance, semaglutide may be prescribed to patients with a Body Mass Index (BMI) of 27 or higher who also have health conditions that increase their risk of heart attack or stroke. The SMC estimates roughly 145,000 people in Scotland may meet these criteria.
How the Treatment Works
Wegovy contains semaglutide, a GLP-1 receptor agonist that suppresses appetite and slows gastric emptying, helping people feel fuller and supporting weight loss. The drug is self-administered at home using a dedicated pen injector.
Benefits Beyond Weight Loss
Clinical trials reported reductions in major cardiovascular events early after starting semaglutide—before substantial weight loss had occurred. That timing suggests the medicine may have direct protective effects on the heart and blood vessels, not only benefits from weight reduction, a point echoed by the National Institute for Health and Care Excellence (NICE).
Safety And Side Effects
Common side effects include nausea, bloating and general gastrointestinal discomfort. As with any medication, patients should discuss potential risks and benefits with their clinician.
Reactions And Context
Dr Mark Strachan, head of the Royal College of Physicians of Edinburgh, called the previous limited access to weight-loss injections in Scotland a "national disgrace," arguing the medicines are among the most effective he has seen in his career.
SMC chairman Dr Rob Peel said the committee was pleased to accept the new medicines and highlighted semaglutide as a useful option to help reduce major cardiovascular events in overweight patients with cardiovascular disease.
Public-Health Impact
Cardiovascular disease is the second leading cause of death in Scotland after cancer and accounts for more than a quarter of all deaths. In the UK each year there are about 100,000 hospital admissions for heart attacks, around 100,000 strokes, and an estimated 350,000 people living with peripheral arterial disease. Experts estimate that, with effective interventions, up to roughly seven in 10 cases of future disease might be prevented in the highest-risk groups.
The SMC decision adds semaglutide to a list of newly recommended treatments and is likely to broaden access across NHS boards in Scotland. Patients and clinicians should refer to local NHS guidance for details on referrals and prescribing pathways.
Help us improve.
